ReAlta lands $40m to back trial of first-in-class infant brain injury therapy
ReAlta Life Sciences has secured $40m to back the continuation of a Phase II study of its lead candidate, pegtarazimod, …
Post
-
-
Sparian commences Phase I trial of SBS-147 for pain treatment
Sparian Biosciences has initiated a Phase I study of SBS-147, an arylepoxamide receptor (AEAr) agonist under development for the treatment …
-
AllRock Bio begins patient dosing in Phase IIa ROCSTAR trial
AllRock Bio has dosed the first patients in the Phase IIa ROCSTAR clinical trial investigating ROC-101, an oral pan-rho-associated protein …
-
Precision Medicine in Early Oncology Trials: Biomarkers as Strategic Drivers
Oncology drug development has shifted decisively towards precision immunotherapies, where biomarker-defined patient populations play a pivotal role. Immuno-oncology now represents …
-
Takeda’s platelet disorder drug triggers up to 91% response rate
A mid-stage trial on Takeda’s anti-CD38 therapy, mezagitamab, has demonstrated the drug’s potential to boost platelet counts in patients with …
-
Spinogenix’s Fragile X Syndrome drug shows normalisation of brain function
Spinogenix’s Fragile X Syndrome (FXS) drug is the first to show rescued well-established resting EEG abnormalities, suggesting a normalisation of …
-
Premature menopause associated with 40% heightened risk of coronary heart disease
According to the US Centers for Disease Control and Prevention, heart disease is the leading cause of death in the …
-
GCAR and Purdue initiate GBM AGILE trial of tinostamustine
The Global Coalition for Adaptive Research (GCAR) and Purdue Pharma have announced the activation of tinostamustine in the Glioblastoma Adaptive …
-
Hemispherian begins Phase I/IIa trial of GLIX1 for GBM
Hemispherian has initiated a first-in-human Phase I/IIa trial of its oral small molecule, GLIX1, in patients with recurrent and progressive …
-
UK launches programme to improve dementia clinical trial enrolment
An initiative to boost dementia clinical trial participation has been launched in the UK. The Dementia Trials Accelerator (DTA) has invited …
-
German study shows promising results for online depression counselling
Clinical depression represents a major public health challenge whose diagnosis and treatment are frequently hindered by social stigma or patient …
-
Insmed freezes Brinsupri’s HS programme on Phase II failure
Insmed is putting a stop to the development of Brinsupri (brensocatib) in hidradenitis suppurativa (HS) after the drug failed to …
-
NeuroTherapia concludes Phase IIa trial of NTRX-07 for Alzheimer’s
NeuroTherapia has concluded its Phase IIa clinical trial of NTRX-07, an orally available molecule, for Alzheimer's disease treatment. The randomised, double-masked …
-
First patient dosed in CatalYm’s Phase IIb visugromab trial
CatalYm has dosed the first patient in its Phase IIb GDFATHER-HCC-01 clinical trial, assessing visugromab, along with chemoimmunotherapy as a …
-
Sanofi’s bispecific scores in respiratory diseases but fails in eczema
Two of Sanofi’s lunsekimig Phase II trials have met their primary endpoints in respiratory disease, while a study in atopic …
